TNFRSF13B and prostate carcinoma: Further, a meta-analysis was performed using four independent cohorts of 991 prostate cancer patients to evaluate the prognostic significance of TNFRSF13B. Patients in the datasets were divided into high and low expression groups according to the median expression levels of TNFRSF13B, and differences in their five-year survival were compared.